Evidence mapPaperPMID 42350779Full record

ReviewActa pharmacologica Sinica2026

Adenosine receptor signaling in vascular diseases: from molecular mechanisms to targeted therapeutics.

De-Hua Yang, Jiao-Jiao Wang, Yu-Qing Huo, Zhi-Ping Liu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

De-Hua YangState Key Laboratory of Bioactive Molecules and Druggability Assessment/Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research/ International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China/College of Pharmacy, Jinan University, Guangzhou, 511436, China.
Jiao-Jiao WangSchool of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, China. wangjiaojiao@gdpu.edu.cn.
Yu-Qing HuoDepartment of Ophthalmology, Baylor College of Medicine, Houston, TX, 77030, USA.
Zhi-Ping LiuState Key Laboratory of Bioactive Molecules and Druggability Assessment/Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research/ International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China/College of Pharmacy, Jinan University, Guangzhou, 511436, China. liuzhiping@jnu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vascular diseases include disorders affecting arteries, veins, and capillaries, and remain the main cause of morbidity and mortality worldwide. The search for new therapeutic targets has led to the discovery of adenosine receptors as key regulators of the pathogenesis of several vascular conditions, including hypertension, atherosclerosis, abdominal aortic aneurysm, cerebral ischemia, and pathological angiogenesis. This review summarises the context-dependent functions of adenosine receptors in these diseases, with particular emphasis on mechanisms associated with endothelial-mesenchymal transition, vascular inflammation, and metabolic reprogramming. The therapeutic relevance of individual adenosine receptor subtypes is also discussed, including current preclinical evidence regarding receptor agonists and antagonists, as well as the potential value of combination-based approaches. Finally, current challenges and future research directions are considered, particularly the development of tissue-specific therapeutic strategies and the application of emerging technologies to improve the clinical translation of mechanistic findings.

Indexed as

adenosineadenosine receptorsendothelial-mesenchymal transitionmetabolismvascular diseasesvascular inflammation

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.